Promoter Polymorphism (-174, G/C) of Interleukin-6 and Arterial Thromboembolic Events: A Meta-Analysis

Related Experiment Video

Updated: Mar 12, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

941

Su Kang Kim1, Joo-Ho Chung1, Oh Young Kwon2

  • 1Kohwang Medical Research Institute, School of Medicine, Kyung Hee University, Seoul, South Korea.

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|November 15, 2016
PubMed

Insights

This meta-analysis found no significant link between the IL-6 gene

Area of Science:

  • Cardiovascular Genetics
  • Molecular Epidemiology
  • Thrombosis Research

Background:

  • Ischemic stroke and myocardial infarction are leading causes of death globally.
  • Interleukin-6 (IL-6) plays a role in arterial thromboembolic events, but its genetic associations are debated.
  • The single-nucleotide polymorphism (SNP) rs1800795 in the IL-6 gene promoter has been investigated for its role in these conditions.

Purpose of the Study:

  • To conduct a meta-analysis to clarify the association between the IL-6 gene promoter SNP (rs1800795) and arterial thromboembolic event susceptibility.
  • To evaluate the relationship between this specific IL-6 polymorphism and the risk of ischemic stroke and myocardial infarction.

Main Methods:

  • A systematic literature search was performed across PubMed, Embase, Google Scholar, and KISS databases.
  • Meta-analysis was conducted using Comprehensive Meta-analysis software, calculating odds ratios (OR) and 95% confidence intervals (CI).
  • Data from 13 eligible studies were analyzed to assess the association between the IL-6 rs1800795 SNP and arterial thromboembolic events.

Main Results:

  • The meta-analysis revealed no statistically significant association between the IL-6 rs1800795 SNP and susceptibility to arterial thromboembolic events.
  • Specific genetic models (C vs. G allele, CC vs. GG, CC+CG vs. GG) showed no significant risk increase or decrease.
  • No significant association was found between the IL-6 SNP and the risk of ischemic stroke or myocardial infarction.

Conclusions:

  • The IL-6 gene rs1800795 SNP is not significantly related to the risk of arterial thromboembolic events.
  • Current evidence suggests this specific genetic variation does not contribute to the susceptibility of ischemic stroke or myocardial infarction.
  • Further research is warranted to definitively confirm these findings and explore other genetic factors.

Keywords:
Interleukin-6Polymorphism, Geneticmeta-analysis

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K
Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions10:16

Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions

Published on: June 28, 2018

33.6K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K